Great West Life Assurance Co. Can acquired a new position in Bausch Health Companies Inc. (NYSE:BHC – Get Rating) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 565,454 shares of the company’s stock, valued at approximately $3,906,000. Great West Life Assurance Co. Can owned 0.16% of Bausch Health Companies as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the business. Merit Financial Group LLC bought a new position in shares of Bausch Health Companies in the third quarter worth about $204,000. Wipfli Financial Advisors LLC bought a new position in Bausch Health Companies during the third quarter valued at approximately $25,000. Zazove Associates LLC bought a new position in Bausch Health Companies during the third quarter valued at approximately $1,426,000. Retirement Planning Co of New England Inc. boosted its stake in Bausch Health Companies by 75.0% during the third quarter. Retirement Planning Co of New England Inc. now owns 23,827 shares of the company’s stock valued at $164,000 after buying an additional 10,215 shares during the last quarter. Finally, Pendal Group Ltd bought a new position in Bausch Health Companies during the third quarter valued at approximately $563,000. Institutional investors own 66.99% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on Bausch Health Companies in a research note on Wednesday, October 12th. They set a “hold” rating for the company. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.60.
Bausch Health Companies Trading Up 0.4 %
Bausch Health Companies (NYSE:BHC – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported $0.76 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.16). The company had revenue of $2.05 billion for the quarter, compared to analyst estimates of $2.09 billion. Bausch Health Companies had a return on equity of 942.47% and a net margin of 3.13%. Analysts predict that Bausch Health Companies Inc. will post 2.97 EPS for the current fiscal year.
Bausch Health Companies Profile
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
Featured Articles
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHC – Get Rating).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.